Literature DB >> 11713719

Can a place of origin of the main cystic fibrosis mutations be identified?

Eva Mateu1, Francesc Calafell, Maria Dolors Ramos, Teresa Casals, Jaume Bertranpetit.   

Abstract

The genetic background of the mutations that most often cause cystic fibrosis (CF) is different from that of non-CF chromosomes in populations of European origin. It is not known whether these haplotype backgrounds could be found at high frequencies in populations in which CF is, at present, not common; such populations would be candidates for the place of origin of CF mutations. An analysis of haplotypes of CF transmembrane conductance regulator, together with their variation in specific CF chromosomes, in a worldwide survey of normal chromosomes shows (1) a very low frequency or absence of the most common CF haplotypes in all populations analyzed and (2) a strong genetic variability and divergence, among various populations, of the chromosomes that carry disease-causing mutations. The depth of the gene genealogy associated with disease-causing mutations may be greater than that of the evolutionary process that gave rise to present-day human populations. The concept of "population of origin" lacks either spatial or temporal meaning for mutations that are likely to have been present in Europeans before the ethnogenesis of present populations; subsequent population processes may have erased the traces of their geographic origin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713719      PMCID: PMC384895          DOI: 10.1086/338243

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  30 in total

1.  Evolution of the delta F508 CFTR mutation.

Authors:  S E Guggino
Journal:  Trends Microbiol       Date:  1999-02       Impact factor: 17.079

2.  Do delta F508 heterozygotes have a selective advantage?

Authors:  C Wiuf
Journal:  Genet Res       Date:  2001-08       Impact factor: 1.588

3.  Worldwide genetic analysis of the CFTR region.

Authors:  E Mateu; F Calafell; O Lao; B Bonné-Tamir; J R Kidd; A Pakstis; K K Kidd; J Bertranpetit
Journal:  Am J Hum Genet       Date:  2000-12-04       Impact factor: 11.025

4.  Salmonella typhi uses CFTR to enter intestinal epithelial cells.

Authors:  G B Pier; M Grout; T Zaidi; G Meluleni; S S Mueschenborn; G Banting; R Ratcliff; M J Evans; W H Colledge
Journal:  Nature       Date:  1998-05-07       Impact factor: 49.962

5.  Variation in short tandem repeats is deeply structured by genetic background on the human Y chromosome.

Authors:  E Bosch; F Calafell; F R Santos; A Pérez-Lezaun; D Comas; N Benchemsi; C Tyler-Smith; J Bertranpetit
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

6.  Active intestinal chloride secretion in human carriers of cystic fibrosis mutations: an evaluation of the hypothesis that heterozygotes have subnormal active intestinal chloride secretion.

Authors:  C Högenauer; C A Santa Ana; J L Porter; M Millard; A Gelfand; R L Rosenblatt; C B Prestidge; J S Fordtran
Journal:  Am J Hum Genet       Date:  2000-10-30       Impact factor: 11.025

7.  On the allelic spectrum of human disease.

Authors:  D E Reich; E S Lander
Journal:  Trends Genet       Date:  2001-09       Impact factor: 11.639

Review 8.  Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections.

Authors:  G B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

9.  A CA repeat in the first intron of the CFTR gene.

Authors:  D S Moulin; A N Smith; A Harris
Journal:  Hum Hered       Date:  1997 Sep-Oct       Impact factor: 0.444

10.  Microsatellite variation and recombination rate in the human genome.

Authors:  B A Payseur; M W Nachman
Journal:  Genetics       Date:  2000-11       Impact factor: 4.562

View more
  11 in total

1.  Ancient founder mutation is responsible for Imerslund-Gräsbeck Syndrome among diverse ethnicities.

Authors:  Cameron M Beech; Sandya Liyanarachchi; Nidhi P Shah; Amy C Sturm; May F Sadiq; Albert de la Chapelle; Stephan M Tanner
Journal:  Orphanet J Rare Dis       Date:  2011-11-13       Impact factor: 4.123

2.  A haplotype framework for cystic fibrosis mutations in Iran.

Authors:  Elahe Elahi; Ahmad Khodadad; Ilya Kupershmidt; Fereshteh Ghasemi; Babak Alinasab; Ramin Naghizadeh; Robert G Eason; Mahshid Amini; Mehran Esmaili; Mohammad R Esmaeili Dooki; Mohammad H Sanati; Ronald W Davis; Mostafa Ronaghi; Yvonne R Thorstenson
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

3.  Accounting for population structure in genetic studies of cystic fibrosis.

Authors:  Hanley Kingston; Adrienne M Stilp; William Gordon; Jai Broome; Stephanie M Gogarten; Hua Ling; John Barnard; Shannon Dugan-Perez; Patrick T Ellinor; Stacey Gabriel; Soren Germer; Richard A Gibbs; Namrata Gupta; Kenneth Rice; Albert V Smith; Michael C Zody; Scott M Blackman; Garry Cutting; Michael R Knowles; Yi-Hui Zhou; Margaret Rosenfeld; Ronald L Gibson; Michael Bamshad; Alison Fohner; Elizabeth E Blue
Journal:  HGG Adv       Date:  2022-05-12

Review 4.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

5.  Epithelial IgG and its relationship to the loss of F508 in the common mutant form of the cystic fibrosis transmembrane conductance regulator.

Authors:  Kate J Treharne; Diane Cassidy; Catharine Goddard; William H Colledge; Andrew Cassidy; Anil Mehta
Journal:  FEBS Lett       Date:  2009-07-09       Impact factor: 4.124

Review 6.  Percutaneous lines for delivering intravenous antibiotics in people with cystic fibrosis.

Authors:  Andrew P Prayle; Matthew N Hurley; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

7.  Detecting Common CFTR Mutations by Reverse Dot Blot Hybridization Method in Cystic Fibrosis First Report from Northern Iran.

Authors:  Mohammad-Reza Esmaeili Dooki; Haleh Akhavan-Niaki; Ali Ghabeli Juibary
Journal:  Iran J Pediatr       Date:  2011-03       Impact factor: 0.364

Review 8.  CFTR activity and mitochondrial function.

Authors:  Angel Gabriel Valdivieso; Tomás A Santa-Coloma
Journal:  Redox Biol       Date:  2013-02-05       Impact factor: 11.799

9.  S737F is a new CFTR mutation typical of patients originally from the Tuscany region in Italy.

Authors:  Vito Terlizzi; Antonella Miriam Di Lullo; Marika Comegna; Claudia Centrone; Elisabetta Pelo; Giuseppe Castaldo; Valeria Raia; Cesare Braggion
Journal:  Ital J Pediatr       Date:  2018-01-03       Impact factor: 2.638

10.  Mutation Analysis of Exons 10 and 17a of CFTR Gene in Patients with Cystic Fibrosis in Kermanshah Province, Western Iran.

Authors:  Abbas Sahami; Reza Alibakhshi; Keyghobad Ghadiri; Hamid Sadeghi
Journal:  J Reprod Infertil       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.